Mereo BioPharma Group PLC (MREO)
3.11
-0.04
(-1.27%)
USD |
NASDAQ |
May 02, 16:00
3.16
+0.05
(+1.61%)
Pre-Market: 09:07
Mereo BioPharma Group Enterprise Value: 383.22M for May 2, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 02, 2024 | 383.22M |
| May 01, 2024 | 388.83M |
| April 30, 2024 | 374.80M |
| April 29, 2024 | 334.12M |
| April 26, 2024 | 331.32M |
| April 25, 2024 | 341.14M |
| April 24, 2024 | 336.93M |
| April 23, 2024 | 336.93M |
| April 22, 2024 | 338.33M |
| April 19, 2024 | 317.29M |
| April 18, 2024 | 318.69M |
| April 17, 2024 | 308.84M |
| April 16, 2024 | 324.27M |
| April 15, 2024 | 321.46M |
| April 12, 2024 | 328.47M |
| April 11, 2024 | 331.28M |
| April 10, 2024 | 359.33M |
| April 09, 2024 | 385.98M |
| April 08, 2024 | 391.59M |
| April 05, 2024 | 408.42M |
| April 04, 2024 | 404.21M |
| April 03, 2024 | 425.25M |
| April 02, 2024 | 421.04M |
| April 01, 2024 | 425.25M |
| March 28, 2024 | 409.82M |
| Date | Value |
|---|---|
| March 27, 2024 | 367.75M |
| March 26, 2024 | 360.73M |
| March 25, 2024 | 363.54M |
| March 22, 2024 | 364.94M |
| March 21, 2024 | 362.13M |
| March 20, 2024 | 381.77M |
| March 19, 2024 | 373.36M |
| March 18, 2024 | 380.37M |
| March 15, 2024 | 383.17M |
| March 14, 2024 | 387.38M |
| March 13, 2024 | 394.39M |
| March 12, 2024 | 437.87M |
| March 11, 2024 | 444.89M |
| March 08, 2024 | 449.09M |
| March 07, 2024 | 457.51M |
| March 06, 2024 | 470.13M |
| March 05, 2024 | 471.54M |
| March 04, 2024 | 488.37M |
| March 01, 2024 | 503.79M |
| February 29, 2024 | 479.95M |
| February 28, 2024 | 469.39M |
| February 27, 2024 | 489.00M |
| February 26, 2024 | 458.19M |
| February 23, 2024 | 462.39M |
| February 22, 2024 | 432.98M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-69.32M
Minimum
May 11 2022
514.21M
Maximum
Jan 29 2024
130.28M
Average
92.56M
Median
May 08 2019
Enterprise Value Benchmarks
| Adaptimmune Therapeutics PLC | 146.78M |
| Biodexa Pharmaceuticals Plc | -2.147M |
| NuCana PLC | -13.56M |
| TC BioPharm (Holdings) PLC | 1.496M |
| Autolus Therapeutics PLC | 853.39M |
Enterprise Value Related Metrics
| Earnings Yield | -6.43% |
| Normalized Earnings Yield | -5.974 |